Clinical trials: Mild Asthma
Asthma
Multiple Dose ASM8 in Mild Asthmatics
To determine the safety and efficacy of multiple doses of ASM8 antisense oligonucleotides in asthmatics.
- Trial name
- NCT00264966
- Testing
- ASM8
- Where
- 3 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Syntara
Asthma Bronchiale
An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma
Flutiform® compared with the individual components Flixotide® (Fluticasone) and Foradil® (Formoterol) in adolescent and adult patients.
- Trial name
- NCT00563056
- Testing
- Flutiform, Flixotide plus Foradil
- Where
- 6 sites in Germany, Hungary and 4 more
- Volunteers
- 227 people
- Sponsor
- Mundipharma Research Limited
Asthma
A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma
The purpose of the study is to assess the propellants,1 - Difluoroethane [HFA-152a] (Test) and 1,1,1,2-Tetrafluoroethane [HFA-134a] (Reference) for their potential to cause the airways to tighten when delivered through…
- Trial name
- NCT06702462
- Testing
- HFA-152A propellant, HFA-134A propellant
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Asthma
Specific Use-Result of Spiriva Respimat® in Asthmatics
The study objective is to investigate the safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent asthma under real-world use
- Trial name
- NCT03188120
- Testing
- Spiriva Respimat
- Where
- Japan
- Volunteers
- 193 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)
To Evaluate the Pharmacodynamic Equivalence of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg base (Sun Pharmaceuticals Industries Limited) to PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg base (Teva Respiratory…
- Trial name
- NCT03528577
- Testing
- Zero-dose, 90 mcg of PROAIR® HFA, 180 mcg of 90 mcg of PROAIR® HFA
- Where
- 8 sites in United States
- Volunteers
- 128 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Asthma
A Study Of GSK679586A When Infused Into Healthy And Mild Asthmatic Volunteers
This is a two part study. Part I is designed to test single doses of GSK678586A in healthy volunteers. Part II is designed to test repeat doses (two doses) of GSK679586A in patients with mild asthma.
- Trial name
- NCT00411814
- Testing
- GSK679586
- Where
- 2 sites in Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation
This study evaluates the efficacy, dose-ranging and safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 110 to 220 mcg per dose in comparison to a DPI Placebo Control and an Albuterol metered dose…
- Trial name
- A006-B3 (NCT02210806)
- Testing
- A006 DPI, Proventil® MDI
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Examine the Effect of Repeat Inhaled Doses of GW870086X on Lung Function in Mild Asthmatic Male Subjects
This study was designed to look at safety aspects and effects of repeat inhaled doses of GW870086X in mild asthmatics to develop this drug for its use in asthma and chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT00483899
- Testing
- GW870086X
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Asthma
Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients
This study will evaluate the efficacy, safety and tolerability of two dosages of a new drug TPI ASM8 administered by inhalation for 14 days to mild to moderate asthmatic patients, aged between 18-65, non-smokers .
- Trial name
- NCT00402948
- Testing
- TPI ASM8, ASM8
- Where
- 10 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Syntara
Asthma
Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma
This study is a double-blind, parallel-group, randomized study of active drug vs placebo in asthma.
- Trial name
- NCT04987944
- Testing
- Zavegepant
- Where
- 10 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma
This is a Phase 1b, single center study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3923868 following repeat doses in mild asthmatics during experimental human…
- Trial name
- NCT05398198
- Testing
- GSK3923868
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Asthma, Efficacy
A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma
This study will be a randomised, double-blind, multiple dose (14 days), placebo-controlled, multi-center study to assess efficacy and safety of three dose levels of AZD7594, given once daily by inhalation, in patients with mild…
- Conditions
- Asthma, Efficacy, Safety
- Trial name
- NCT02479412
- Testing
- 800 μg AZD7594 once daily, 250 µg AZD7594 once daily, 58 µg AZD7594 once daily
- Where
- 10 sites in Bulgaria, Germany
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Asthma
Efficacy of TPI ASM8 During a 14-Day Allergen Challenge
This is a randomized, double-blind, placebo-controlled, 3-way crossover trial to evaluate the efficacy and safety of two different doses of inhaled TPI ASM8 administered daily for 14 days for the treatment of allergic asthma and…
- Trial name
- NCT01158898
- Testing
- TPI ASM8
- Where
- 4 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Syntara
Asthma
Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma Patients
This study aims to study the efficacy (as measured by change in FEV1) and safety of two-week administration of oral QAV680 in the treatment of patients with asthma.'
- Trial name
- NCT00814216
- Testing
- QAV680, Fluticasone Propionate
- Where
- 7 sites in Germany, India
- Volunteers
- 37 people
- Sponsor
- Novartis
Asthma
A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects
PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.
- Trial name
- NCT00877539
- Testing
- PF-03526299, Fluticasone propionate
- Where
- 2 sites in United Kingdom
- Volunteers
- 29 people
- Sponsor
- Pfizer
Asthma, Mild Asthma
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
The primary objectives of the study are: Part 1: to characterize the potency and variability of dose response on efficacy (Provocative concentration of methacholine causing at least a 20% fall in forced expiratory volume (FEV1)…
- Trial name
- NCT06433921
- Testing
- Salbutamol HFA-152a, Salbutamol HFA-134a
- Where
- United Kingdom
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Evaluate the Safety and Use of Human Rhinovirus in Healthy and Asthmatic Participants (MK-0000-218)
The purpose of this study is to establish the safety and tolerability of Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) human rhinovirus 16 (RV16UB) in healthy and asthmatic participants, and…
- Trial name
- NCT01866306
- Testing
- RV16UB, LABA
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma
The primary objective is to determine if CIC 50 mg/day or 200 mg/day (ex-valve) administered once daily in the morning is non-inferior to placebo with respect to growth velocity in children with mild persistent asthma following a…
- Trial name
- NCT00270348
- Testing
- ciclesonide
- Volunteers
- 450 people
- Sponsor
- Sanofi
Asthma
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients
The present trial is an exploratory study aiming at evaluating the safety, tolerability, and efficacy of a 15-day, once daily administration of 10 mg PBF-680 in subjects with persistent, mild-to-moderate atopic asthma.
- Trial name
- ADENOASMA (NCT03774290)
- Testing
- PBF-680
- Where
- Spain
- Volunteers
- 107 people
- Sponsor
- Palobiofarma SL
Allergic Asthma
Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
This study is to designed to test the role of complement in the late asthmatic response to allergen challenge in mild asthma, as an indicator of the possible role of complement in the broader asthmatic population.
- Trial name
- NCT00485576
- Testing
- eculizumab
- Where
- 2 sites in Canada
- Volunteers
- 21 people
- Sponsor
- Alexion Pharmaceuticals, Inc.